GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Market Cap

ALX Oncology Holdings (ALX Oncology Holdings) Market Cap : $790.36 Mil (As of May. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). ALX Oncology Holdings's share price for the quarter that ended in Mar. 2024 was $11.15. ALX Oncology Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 50.28 Mil. Therefore, ALX Oncology Holdings's market cap for the quarter that ended in Mar. 2024 was $560.59 Mil.

ALX Oncology Holdings's quarterly market cap increased from Sep. 2023 ($197.53 Mil) to Dec. 2023 ($743.79 Mil) but then declined from Dec. 2023 ($743.79 Mil) to Mar. 2024 ($560.59 Mil).

ALX Oncology Holdings's annual market cap declined from Dec. 2021 ($872.22 Mil) to Dec. 2022 ($460.51 Mil) but then increased from Dec. 2022 ($460.51 Mil) to Dec. 2023 ($743.79 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ALX Oncology Holdings's Enterprise Value for Today is $665.55 Mil.


ALX Oncology Holdings Market Cap Historical Data

The historical data trend for ALX Oncology Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ALX Oncology Holdings Market Cap Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 3,434.60 872.22 460.51 743.79

ALX Oncology Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 184.70 307.85 197.53 743.79 560.59

Competitive Comparison of ALX Oncology Holdings's Market Cap

For the Biotechnology subindustry, ALX Oncology Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALX Oncology Holdings's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Market Cap falls into.



ALX Oncology Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

ALX Oncology Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$14.89*49.952
=$743.79

ALX Oncology Holdings's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$11.15*50.2772
=$560.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ALX Oncology Holdings  (NAS:ALXO) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


ALX Oncology Holdings Market Cap Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


ALX Oncology Holdings (ALX Oncology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Executives
Shelly Pinto officer: VP, Finance and CAO 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia officer: Chief Financial Officer ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Sophia Randolph officer: Chief Medical Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons director, officer: President and CEO C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas director C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Jason Lettmann director, 10 percent owner C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Lsv Associates, Llc 10 percent owner 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Goodman Corey S director, 10 percent owner, other: Executive Chairman 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Rekha Hemrajani director 3928 POINT EDEN WAY, HAYWARD CA 94545
Venbio Global Strategic Fund, L.p. 10 percent owner, other: See Remarks 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Vivo Opportunity Fund, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Vivo Opportunity, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Steffen Pietzke officer: VP Fin & Chief Acct Officer C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538